Economic evaluation studies in nuclear medicine: The need for standardization

European Journal of Nuclear Medicine

Volumn 26, Issue 6, 1999, Pages 663-680

  Dietlein, Markus ^a,c   Knapp, Wolfram H ^a   Lauterbach, Karl W ^b   Schicha, Harald ^a  

^a Department of Nuclear Medicine ^*  (Germany)

^b Institute of Public Health   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Cost effectiveness; Cost utility; Imaging; Nuclear medicine; Radiopharmaceuticals

Indexed keywords

FLUORODEOXYGLUCOSE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; RADIOACTIVE IODINE; SOMATOSTATIN RECEPTOR; THYROTROPIN;

ALGORITHM; CANCER STAGING; CARCINOID; CLINICAL TRIAL; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DATA BASE; DECISION THEORY; ECONOMIC EVALUATION; GRAVES DISEASE; HUMAN; LUNG NON SMALL CELL CANCER; METASTASIS; MORBIDITY; NUCLEAR MEDICINE; PARATHYROID ADENOMA; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RETROSPECTIVE STUDY; REVIEW; SCINTIGRAPHY; STANDARDIZATION; SURVIVAL RATE; THYROTROPIN BLOOD LEVEL; TOXIC GOITER; TREATMENT OUTCOME;

COST-BENEFIT ANALYSIS; COSTS AND COST ANALYSIS; DECISION SUPPORT TECHNIQUES; EUROPE; EVALUATION STUDIES; HUMANS; MODELS, ECONOMIC; NUCLEAR MEDICINE; OUTCOME ASSESSMENT (HEALTH CARE); RADIONUCLIDE IMAGING; TECHNOLOGY ASSESSMENT, BIOMEDICAL; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0032986289     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590050436     Document Type: Review

References (66)

1. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ 1996; 313: 275-283.
2. Manson J, Drummond M. Reporting guidelines for economic studies. Health Econ 1995; 4: 85-94.
3. Siegel JE, Weinstein MC, Russel LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. JAMA 1996; 276: 1339-1341.
4. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 1253-1258.
5. Johannesson M, Jönsson B, Karlsson G. Outcome measurement in economic evaluation. Health Econ 1996; 5: 279-296.
6. Gambhir SS. Cost-effectiveness analysis in nuclear medicine [commentary]. J Nucl Med 1998; 39: 17N-18N.
7. Radensky PW, Hilton TC, Fulmer H, McLaughlin BA, Stowers SA. Potential cost effectiveness of initial myocardial per fusion imaging for assessment of emergency department patients with chest pain. Am J Cardiol 1997; 79: 595-599.
8. Weissman IA, Dickinson CZ, Dworkin H, O'Neill WW, Juni JE. Cost-effectiveness of myocardial perfusion imaging with SPECT in the emergency department evaluation of patients with unexplained chest pain. Radiology 1996; 199: 353-357.
9. Dietlein M, Moka D, Dederichs B et al. Cost-effectiveness analysis: radioiodine or antithyroid drugs as first-line therapy of hyperthyroidism due to Graves' disease [in German]. Nu klearmedizin 1999; 38: 7-14.
10. Earle CC, Coyle D, Evans WK. Cost-effectiveness analysis in oncology. Ann Oncol 1998; 9: 475-482.
11. Ament A, Baltussen R. The interpretation of results of economic evaluation: explicating the value of health. Health Econ 1997; 6: 625-635.
12. Johannesson M, Meltzer D. Some reflections on cost-effectiveness analysis. Health Econ 1998; 7: 1-7.
13. Gambhir SS, Hoh CK, Phelps ME, Madar I, Maddahi J. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med 1996; 37: 1428-1436.
14. Hillner BE. Decision analysis: MIBI imaging of nonpalpable breast abnormalities. J Nucl Med 1997; 38: 1772-1778.
15. Waxman AD. A perspective on decision analysis modeling as it relates to sestamibi imaging of nonpalpable breast abnor malities [editorial]. J Nucl Med 1997; 38: 1778-1780.
16. Denham DW, Norman J. Cost-effectiveness of preoperative sestamibi scan for primary hyperparathyroidism is dependent solely upon the surgeon's choice of operative procedure. J Am Coll Surg 1998; 186: 293-304.
17. Sofferman RA, Nathan MH. The ectopic parathyroid adenoma. Arch Otolaryngol Head Neck Surg 1998; 124: 649-654.
18. Hilleman DE, Lucas BD, Mohiuddin SM, Holmberg MJ. Cost-minimization analysis of intravenous adenosine and di pyridamole in thallous chloride T1 201 SPECT myocardial perfusion imaging. Ann Pharmacother 1997; 31: 974-979.
19. Holmberg MJ, Mohiuddin SM, Hilleman DE, Lucas BD, Wadibia EC. Outcomes and costs of positron emission tomog raphy: comparison of intravenous adenosine and intravenous dipyridamole. Clin Ther 1997; 19: 570-581.
20. Spencer RP, Kayani N, Karimeddini MK. Radioiodine therapy of hyperthyroidism: socioeconomic considerations [editorial]. J Nucl Med 1985; 663-665.
21. Dietlein M, Geckle L, Overbeck T et al. Cost-minimization analysis for the treatment of hyperthyroidism: comparison of goiter resection with radioiodine therapy [in German]. Nu klearmedizin 1997; 36: 150-156.
22. Dietlein M, Lauterbach KW, Schicha H. Treatment of toxic nodular goitres: comparative costing of radioiodine therapy and surgery. Exp Clin Endocrinol Diabetes 1998; 106 (Suppl 4): S66-S70.
23. Dietlein M, Troche CJ, Moka D et al. Consequences of new patient discharge guidelines for iodine-131 therapy cost management [in German]. Nuklearmedizin 1998; 37: 26-33.
24. Power EJ, Eisenberg JM. Are we ready to use cost-effectiveness analysis in health-care decision-making? Med Care 1998; 36 (Suppl 5): MS10-MS17.
25. Woodward RS, Schnitzler MA, Kvols LS. Reduced uncertainty as a diagnostic benefit: an initial assessment of somatostatic receptor scintigraphy's value in detecting distant metastases of carcinoid liver tumours. Health Econ 1998; 149-160.
26. Danese MD, Powe NR, Sawin CT, Ladenson PW. Screening for mild thyroid failure at the periodic health examination. A decision and cost-effectiveness analysis. JAMA 1996; 276: 285-292.
27. Eckman MH, Greenfield S, Mackey WC, Wong JB. Foot in fection in diabetic patients. Decision and cost-effectiveness analyses. JAMA 1995; 273: 712-720.
28. Patterson RE, Eisner RL, Horowitz SF. Comparison of cost-effectiveness and utility of exercise ECG, single photon emission computed tomography, positron emission tomography, and coronary angiography for diagnosis of coronary artery disease. Circulation 1995; 91: 54-65.
29. Michel BC, Seerden RJ, Rutten FFH, van Beek EJR, Büller HR. The cost-effectiveness of diagnostic strategies in patients with suspected pulmonary embolism. Health Econ 1996; 5: 307-318.
30. Perrier A, Buswell L, Bounameaux H et al. Cost-effectiveness of noninvasive diagnostic aids in suspected pulmonary embo lism. Arch Intern Med 1997; 157: 2309-2316.
31. Hachamovitch R, Berman DS, Shaw LJ et al. Incremental prognostic value of myocardial perfusion single photon emis sion computed tomography for the prediction of cardiac death. Circulation 1998; 97: 535-543.
32. Gudgeon CA, Werner TD, Dent DM. A re-evaluation of iso tope screening for skeletal metastases in node-negative breast cancer. S Afr Med J 1996; 86: 166-169.
33. Kennedy H, Kennedy N, Barclay M, Horobin M. Cost effi ciency of bone scans in breast cancer. Clin Oncol 1991; 3: 73-77.
34. Levran Z, Gonzalez JA, Diokno AC, Jafri SZ, Steinert BW. Are pelvic computed tomography, bone scan and pelvic lym phadenectomy necessary in the staging of prostatic cancer? Br J Urol 1995; 75: 778-781.
35. Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993; 269: 57-60.
36. Yeh KA, Fortunato L, Ridge JA et al. Routine bone scanning in patients with T1 and T2 breast cancer: a waste of money. Ann Surg Oncol 1995; 2: 319-324.
37. Kwekkeboom DJ, Lamberts SWJ, Habbema JDF, Krenning EP. Cost-effectiveness analysis of somatostatin receptor scin tigraphy. J Nucl Med 1996; 37: 886-892.
38. Hoh CK, Glaspy J, Rosen P et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. J Nucl Med 1997; 38: 343-348.
39. Dwamena BA, Kloos RT, Fendrick M et al. Diagnostic evaluation of the adrenal incidentaloma: decision and cost-effective ness analyses. J Nucl Med 1998; 39: 707-712.
40. Maddahi J, Gambhir SS. Cost-effective selection of patients for coronary angiography. J Nucl Cardiol 1997; 4: S141-S151.
41. Delbeke D, Vitola JV, Sandler MP et al. Staging recurrent metastatic colorectal carcinoma with PET. J Nucl Med 1997; 38: 1196-1201.
42. Valk PE, Pounds TR, Tesar RD, Hopkins DM, Haseman MK. Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol 1996; 23: 737-743.
43. Small GW, Leiter F. Neuroimaging for diagnosis of dementia. J Clin Psychiatry 1998; 59 (Suppl 11): 4-7.
44. Underwood SR, Godman B, Salyani S et al. Economics of myocardial perfusion imaging in Europe - the EMPIRE study. Eur Heart J 1999; 20: 157-166.
45. Hardisty CA, Jones SJ, Hedley AJ, et al. Clinical outcome and costs of care in radioiodine treatment of hyperthyroidism. J R Coll Physicians Lond 1990; 24: 36-42.
46. Ljunggren JG, Törring O, Wallin G, et al. Quality of life aspects and costs in treatment of Graves' hyperthyroidism with antithyroid drugs, surgery, or radioiodine: results from a prospective, randomized study. Thyroid 1998; 8: 653-659.
47. Henkin RE. "Frankly, my dear, I don't give a damn" [editori al]. J Nucl Med 1996; 37: 1073-1074.
48. Rubin DN, Ballal RS, Marwick TH. Outcomes and cost implications of a clinical-based algorithm to guide the discriminate use of stress imaging before noncardiac surgery. Am Heart J 1997; 134: 83-92.
49. Berman DS, Hachamovitch R, Kiat H et al. Incremental value of prognostic testing in patients with known or suspected ischemic heart disease: a basis for optimal utilization of exercise technetium-99 m sestamibi myocardial perfusion single-photon emission computed tomography. J Am Coll Cardiol 1995; 26: 639-647.
50. Jacobs P, Baladi JF. Biases in cost measurement for economic evaluation studies in health care. Health Econ 1996; 5: 525-529.
51. Wright CJ, Mueller CB. Screening mammography and public health policy: the need for perspective. Lancet 1995; 346: 29-32.
52. Fuchs VR, Garber AM. The new technology assessment. N Engl J Med 1990; 323: 673-677.
53. Steinberg EP, Whittle J, Anderson GF. Impact of claims data research on clinical practice. Int J Technol Assess Health Care 1990; 6: 282-287.
54. Pauker SG, Kassirer JP. Decision analysis. N Engl J Med 1987; 316: 250-258.
55. Cook DJ, Sackett DL, Spitzer WO. Methodologic guidelines for systematic reviews of randomized control trials in health care from the Potsdam consultation on meta-analysis. J Clin Epidemiol 1995; 48: 167-171.
56. Sheldon TA. Problems of using modelling in the economic evaluation of health care. Health Econ 1996; 5: 1-11.
57. Al-Sugair A, Coleman RE. Applications of PET in lung cancer. Semin Nucl Med 1998; 28: 303-319.
58. Sasaki M, Ichiya Y, Kuwabara Y et al. The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography. Eur J Nucl Med 1996; 23: 741-747.
59. Steinert HC, Hauser M, Allemann F et al. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 1997; 202: 441-446.
60. Vansteenkiste JF, Stroobants SG, Dupont PJ et al. FDG-PET scan in potentially operable non-small cell lung cancer: do anatometabolic PET-CT fusion images improve the localisa tion of regional lymph node metastases? Eur J Nucl Med 1998; 25: 1495-1501.
61. Gupta NC, Maloof J, Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med 1996; 37: 943-948.
62. Coleman RE, Tesar RD. Clinical PET: are we ready? [com mentary]. J Nucl Med 1997; 38: 16N.
63. Papatheofanis FJ. Technology assessment, managed healthcare and nuclear medicine [newsline]. J Nucl Med 1997; 38: 13N-14N.
64. Palmedo H, Biersack HJ, Lastoria S, et al. Scintimammography with technetium-99m methoxyisobutylisonitrile: results of a prospective European multicentre trial. Eur J Nucl Med 1998; 25: 375-385.
65. Gal R, Ahmad M. Cost-saving approach to normal technetium-99 m sestamibi myocardial perfusion scan. Am J Cardiol 1996; 78: 1047-1049.
66. Milan E, Giubbini R, Gioio G, Terzi A, Iskandrian AE. A cost-effective sestamibi protocol in the managed health care era. J Nucl Cardiol 1997; 4: 509-514.